Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 75

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 75
---
 to our business.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees
on any issued patent are due to be paid to the USPTO and other patent agencies in several stages over the lifetime of the patent. The
USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and
other similar provisions during the patent application process. Although an inadvertent lapse can in many cases be cured by payment of
a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance
events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within
prescribed time limits, non-payment of fees, and failure to properly submit documents requesting an extension of time. In any such event,
our competitors might be able to enter the market, which would have a material adverse effect on our business.

<div align='center'>34</div>

The terms of our patents may not be sufficient to effectively protect our drug and diagnostics technology candidates and business.

In most countries in which
we file, including the United States, the term of an issued patent is generally 20 years from the earliest claimed filing date of a non-provisional
patent application in the applicable country. Although various extensions may be available, the life of a patent and the protection it
affords is limited. For example, depending upon the timing, duration and specifics of the FDA regulatory approval for our drug candidates,
one or more of our U.S. patents, if issued, might be eligible for limited patent term restoration under the Drug Price Competition and
Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension
of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. Patent term extensions,
however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval by the FDA, and only one
patent can be extended for a particular drug. The application for patent term